Watchful waiting in prostate cancer: Review and policy proposals

BJU International

Volumn 92, Issue 8, 2003, Pages 851-859

  Schroder F H ^a   De Vries, S H ^a   Bangma, C H ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER GRADING; CANCER INCIDENCE; CANCER MORTALITY; CANCER PATIENT; CANCER SCREENING; CANCER SURVIVAL; DIAGNOSTIC IMAGING; HEALTH CARE POLICY; HEALTH PROGRAM; HUMAN; LABORATORY TEST; PATIENT SELECTION; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CARCINOMA; REVIEW; TRANSRECTAL ULTRASONOGRAPHY; TREATMENT INDICATION;

BIOPSY; FOLLOW-UP STUDIES; HEALTH POLICY; HUMANS; MALE; PATIENT SELECTION; PROGNOSIS; PROSPECTIVE STUDIES; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 0345689333     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410X.2003.04493.x     Document Type: Review

References (55)

1. Ferlay JBF, Pisani P, Parkin DM. GLOBOCAN 2000. cancer incidence, mortality and prevalence worldwide. Lyon: IARC press, 2001
2. Klotz LH, Choo R, Morton G, Danjoux C. Expectant management with selective delayed intervention for favorable-risk prostate cancer. Can J Urol 2002; 9 (Suppl. 1): 2-7
3. Lu-Yao GL, Yao SL. Population-based study of long-term survival in patients with clinically localised prostate cancer. Lancet 1997; 349: 906-10
4. Albertsen PC, Hanley JA, Gleason DF, Barry MJ. Competing risk analysis of men aged 55-74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 1998; 280: 975-80
5. Chodak GW, Thisted RA, Gerber GS et al. Results of conservative management of clinically localized prostate cancer. N Engl J Med 1994; 330: 242-8
6. Narain V, Bianco FJ Jr, Grignon DJ, Sakr WA, Pontes JE, Wood DP Jr. How accurately does prostate biopsy Gleason score predict pathologic findings and disease free survival? Prostate 2001; 49: 185-90
7. Auvin A, Maattanen L, Stenman UH et al. Lead-time in prostate cancer screening (Finland). Cancer Causes Control 2002; 13: 279-85
8. Draisma GBR, Otto SJ, van der Cruijsen IW et al. Lead-times and overdetection in PSA screening-an estimate based on results from the ERSPC Trial, Section Rotterdam. JNCI 2003;
9. Rietbergen JB, Hoedemaeker RF, Kruger AE, Kirkels WJ, Schroder FH. The changing pattern of prostate cancer at the time of diagnosis: characteristics of screen detected prostate cancer in a population based screening study. J Urol 1999; 161: 1192-8
10. Holmberg L, Bill-Axelson A, Helgesen F et al. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 2002; 347: 781-9
11. Partin AW, Mangold LA, Lamm DM, Walsh PC, Epstein JI, Pearson JD. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology 2001; 58: 843-8
12. McLaren DB, McKenzie M, Duncan G, Pickles T. Watchful waiting or watchful progression? Prostate specific antigen doubling times and clinical behavior in patients with early untreated prostate carcinoma. Cancer 1998; 82: 342-8
13. Choo R, Klotz L, Danjoux C et al. Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. J Urol 2002; 167: 1664-9
14. Koppie TM, Grossfeld GD, Miller DYuJ, Stier D, Broering JM et al. Patterns of treatment of patients with prostate cancer initially managed with surveillance: results from The CaPSURE database. Cancer of the Prostate Strategic Urological Research Endeavor. J Urol 2000; 164: 81-8
15. Stephenson AJ, Aprikian AG, Souhami L et al. Utility of PSA doubling time in follow-up of untreated patients with localized prostate cancer. Urology 2002; 59: 652-6
16. Zietman AL, Thakral H, Wilson L, Schellhammer P. Conservative management of prostate cancer in the prostate specific antigen era: the incidence and time course of subsequent therapy. J Urol 2001; 166: 1702-6
17. Carter HB, Walsh PC, Landis P, Epstein JI. Expectant management of nonpalpable prostate cancer with curative intent: preliminary results. J Urol 2002; 167: 1231-4
18. Post PN, Hansen BE, Kil PJ, Janssen-Heijnen ML, Coebergh JW. The independent prognostic value of comorbidity among men aged < 75 years with localized prostate cancer: a population-based study. BJU Int 2001; 87: 821-6
19. Fowler JE Jr, Terrell FL, Renfroe DL. Co-morbidities and survival of men with localized prostate cancer treated with surgery or radiation therapy. J Urol 1996; 156: 1714-8
20. Barry MJ, Albertsen PC, Bagshaw MA et al. Outcomes for men with clinically nonmetastatic prostate carcinoma managed with radical prostatectomy, external beam radiotherapy, or expectant management: a retrospective analysis. Cancer 2001; 91: 2302-14
21. Ravery V, Chastang C, Toublanc M, Boccon-Gibod L, Delmas V. Percentage of cancer on biopsy cores accurately predicts extracapsular extension and biochemical relapse after radical prostatectomy for T1-T2 prostate cancer. Eur Urol 2000; 37: 449-55
22. Nelson CPRM, Strawderman M, Montie JE, Sanda MG. Preoperative parameters for predicting early prostate cancer recurrence after radical prostatectomy. Urology 2002; 59: 740-5
23. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994; 271: 368-74
24. D'Amico AV, Whittington R, Malkowicz SB et al. Combination of the preoperative PSA level, biopsy Gleason score, percentage of positive biopsies, and MRI T-stage to predict early PSA failure in men with clinically localized prostate cancer. Urology 2000; 55: 572-7
25. Weldon VE, Tavel FR, Neuwirth H, Cohen R. Failure of focal prostate cancer on biopsy to predict focal prostate cancer: the importance of prevalence J Urol 1995; 154: 1074-7
26. Lattouf JB, Saad F. Gleason score on biopsy: is it reliable for predicting the final grade on pathology? BJU Int 2002; 90: 694-8
27. San Francisco IF, DeWolf WC, Rosen S, Upton M, Olumi AF. Extended prostate needle biopsy improves concordance of Gleason grading between prostate needle biopsy and radical prostatectomy. J Urol 2003; 169: 136-40
28. Grossklaus DJ, Coffey CS, Shappell SB, Jack GS, Cookson MS. Prediction of tumour volume and pathological stage in radical prostatectomy specimens is not improved by taking more prostate needle-biopsy cores. BJU Int 2001; 88: 722-6
29. Egevad L, Norlen BJ, Norberg M. The value of multiple core biopsies for predicting the Gleason score of prostate cancer. BJU Int 2001; 88: 716-21
30. Bastacky SI, Walsh PC, Epstein JI. Relationship between perineural tumor invasion on needle biopsy and radical prostatectomy capsular penetration in clinical stage B adenocarcinoma of the prostate. Am J Surg Pathol 1993; 17: 336-41
31. Bonin SR, Hanlon AL, Lee WR, Movsas B, al-Saleem TI, Hanks GE. Evidence of increased failure in the treatment of prostate carcinoma patients who have perineural invasion treated with three-dimensional conformal radiation therapy. Cancer 1997; 79: 75-80
32. Huland H, Hammerer P, Henke RP, Huland E. Preoperative prediction of tumor heterogeneity and recurrence after radical prostatectomy for localized prostatic carcinoma with digital rectal, examination prostate specific antigen and the results of 6 systematic biopsies. J Urol 1996; 155: 1344-7
33. Peller PA, Young DC, Marmaduke DP, Marsh WL, Badalament RA. Sextant prostate biopsies. A histopathologic correlation with radical prostatectomy specimens. Cancer 1995; 75: 530-8
34. Freedland SJ, Csathy GS, Dorey F, Aronson WJ. Clinical utility of percent prostate needle biopsy tissue with cancer cutpoints to risk stratify patients before radical prostatectomy. Urology 2002; 60: 84-8
35. Terris MK, Haney DJ, Johnstone IM, McNeal JE, Stamey TA. Prediction of prostate cancer volume using prostate-specific antigen levels, transrectal ultrasound, and systematic sextant biopsies. Urology 1995; 45: 75-80
36. Badalament RA, Miller MC, Peller PA et al. An algorithm for predicting nonorgan confined prostate cancer using the results obtained from sextant core biopsies with prostate specific antigen level. J Urol 1996; 156: 1375-80
37. Elgamal AA, Van Poppel HP, Van de Voorde WM, Van Dorpe JA, Oyen RH, Baert LV. Impalpable invisible stage T1c prostate cancer. Characteristics and clinical relevance in 100 radical prostatectomy specimens - a different view. J Urol 1997; 157: 244-50
38. Haese A, Chaudhari M, Miller MC et al. Quantitative biopsy pathology for the prediction of pathologically organ-confined prostate carcinoma: a multiinstitutional validation study. Cancer 2003; 97: 969-78
39. Choo R, DeBoer G, Klotz L et al. PSA doubling time of prostate carcinoma managed with watchful observation alone. Int J Radiat Oncol Biol Phys 2001; 50: 615-20
40. Carter HB, Epstein JI, Chan DW, Fozard JL, Pearson JD. Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancer. JAMA 1997; 277: 1456-60
41. Do V, Choo R, De Boer G et al. The role of serial free/total prostate-specific antigen ratios in a watchful observation protocol for men with localized prostate cancer. BJU Int 2002; 89: 703-9
42. Gleave MGS, Rennie P. Recent advances in prostate cancer, BPH;. Proceedings of the IV Congress on Progress and Controversies in Oncological Urology (PACIOU IV) Held in Rotterdam, the Netherlands, April 11-13, 1996. In Schroeder FH ed. New York, London: Parthenon Publishing, 1996: 109-20
43. Davidson PJ, Hop W, Kurth KH, Fossa SD, Waehre H, Schroeder FH. Progression in untreated carcinoma of the prostate metastatic to regional lymph nodes (stage t0-4,N1-3.M0,D1). European Organization for Research and Treatment of Cancer Genitourinary Group. J Urol 1995; 154: 2118-22
44. Carter HB, Morrell CH, Pearson JD et al. Estimation of prostatic growth using serial prostate-specific antigen measurements in men with and without prostate disease. Cancer Res 1992; 52: 3323-8
45. Ciatto S, Bonardi R, Lombardi C, Zappa M, Gervasi G, Cappelli G. Analysis of PSA velocity in 1666 healthy subjects undergoing total PSA determination at two consecutive screening rounds. Int J Biol Markers 2002; 17: 79-83
46. Schroder FH, Kranse R, Barbet N, Hop WC, Kandra A, Lassus M. Prostate-specific antigen: a surrogate endpoint for screening new agents against prostate cancer? Prostate 2000; 42: 107-15
47. Guess B, Jennrich R, Johnson H, Redheffer R, Scholz M. Using splines to detect changes in PSA doubling times. Prostate 2003; 54: 88-94
48. Colette L, de Reijke T, Schröder F and Group Amoteg-U. Prostate-specific antigen - a prognostic marker of survival in good prognosis metastatic prostate cancer. Journal? 2003 in press
49. Stamey TA, Kabalin JN, Ferrari M, Yang N. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. IV. Anti-androgen treated patients. J Urol 1989; 141: 1088-90
50. Schmid HP, McNeal JE, Stamey TA. Observations on the doubling time of prostate cancer. The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer Volume Cancer 1993; 71: 2031-40
51. Stamey TA, Johnstone IM, McNeal JE, Lu AY, Yemoto CM. Preoperative serum prostate specific antigen levels between 2 and 22 ng/ml correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng/ml. J Urol 2002; 167: 103-11
52. Hanks GE, Hanlon AL, Lee WR, Slivjak A, Schultheiss TE. Pretreatment prostate-specific antigen doubling times, clinical utility of this predictor of prostate cancer behavior. Int J Radiat Oncol Biol Phys 1996; 34: 549-53
53. Goluboff ET, Heitjan DF, DeVries GM, Katz AE, Benson MC, Olsson CA. Pretreatment prostate specific antigen doubling times: use in patients before radical prostatectomy. J Urol 1997; 158: 1876-8
54. Epstein JI, Walsh PC, Carter HB. Dedifferentiation of prostate cancer grade with time in men followed expectantly for stage T1c disease. J Urol 2001; 166: 1688-91
55. Vis AN, Boerma MO, Ciatto S, Hoedemaeker RF, Schroder FH, van der Kwast TH. Detection of prostate cancer: a comparative study of the diagnostic efficacy of sextant transrectal versus sextant transperineal biopsy. Urology 2000; 5